Actinium Pharmaceuticals, Inc.ATNMNYSE
Loading
Cash Flow Under PressureContracting
Percentile Rank13
Studio
Year-over-Year Change

Operating cash flow minus capital expenditures

Percentile
P13
Within normal range
vs 3Y Ago
-3x
Contraction
Streak
2 yr
Consecutive growthContracting
PeriodValueYoY Change
TTM$-25.04M+24.3%
2024$-33.08M+30.3%
2023$-47.49M-673.7%
2022$8.28M+139.4%
2021$-21.00M+4.0%
2020$-21.87M-1.6%
2019$-21.53M-4.2%
2018$-20.67M+4.2%
2017$-21.58M-3.5%
2016$-20.85M-